Missouri 2026 Regular Session Status: In Committee

SB 1223 — Requires disclosure for certain products produced, sold, or distributed in Missouri

Last action — Second Read and Referred S Families, Seniors and Health Committee

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced December 01, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Stalled 14% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

SB 1223 - This act requires any product to be conspicuously labeled "Potential Gene Therapy Product" if the product has been created to act as, or otherwise exposed to processes resulting in the product acting as, a gene therapy or that could impact, alter, or introduce genetic material or a genetic change into the user or individuals exposed to the product, unless the product is reasonably known to be a gene therapy product, in which case the product shall be labeled "Gene Therapy Product". Upon the written request of a Missouri resident, any entity producing, selling, or distributing a product in this state with the capacity to infect an individual with a disease or expose an individual to genetically modified material shall provide information to the resident on the ways in which individuals who did not directly obtain or use the product may be exposed to the product or a component of the product. These provisions apply as well to any governmental agency, product manufacturer, or organization with an interest in the production, sale, or distribution of such product, as described in the act. All entities subject to disclosure requirements under this provision shall provide the requested information within at least 21 days after receipt of the request. Finally, any entity that makes a product available in Missouri that could infect, transmit to, or otherwise be absorbed in any individual in any way that could act as a medical intervention, vaccine, drug, or genetic modification shall obtain fully informed consent from all potential exposed individuals prior to such exposure. This act is identical to SB 252 (2025), SB 1186 (2024), and HB 1169 (2023). SARAH HASKINS

Bill Text

Action History

  1. Second Read and Referred S Families, Seniors and Health Committee

  2. S First Read

  3. Prefiled

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 198 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (198)

198 members have not signed on to this bill.

Show all 198 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety civil-rights healthcare health-insurance technology
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 1223 do?
SB 1223 - This act requires any product to be conspicuously labeled "Potential Gene Therapy Product" if the product has been created to act as, or otherwise exposed to processes resulting in the product acting as, a gene therapy or that could impact, alter, or introduce genetic material or a genetic change into the user or individuals exposed to the product, unless the product is reasonably known to be a gene therapy product, in which case the product shall be labeled "Gene Therapy Product". Upon the written request of a Missouri resident, any entity producing, selling, or distributing a product in this state with the capacity to infect an individual with a disease or expose an individual to genetically modified material shall provide information to the resident on the ways in which individuals who did not directly obtain or use the product may be exposed to the product or a component of the product. These provisions apply as well to any governmental agency, product manufacturer, or organization with an interest in the production, sale, or distribution of such product, as described in the act. All entities subject to disclosure requirements under this provision shall provide the requested information within at least 21 days after receipt of the request. Finally, any entity that makes a product available in Missouri that could infect, transmit to, or otherwise be absorbed in any individual in any way that could act as a medical intervention, vaccine, drug, or genetic modification shall obtain fully informed consent from all potential exposed individuals prior to such exposure. This act is identical to SB 252 (2025), SB 1186 (2024), and HB 1169 (2023). SARAH HASKINS
Who sponsors SB 1223?
SB 1223 is sponsored by Mike Moon.
What is the current status of SB 1223?
This bill is in committee in the Senate. Introduced December 01, 2025. It must pass committee before a floor vote.
Where can I track SB 1223?
Track SB 1223 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 1223

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 1223

Last checked for changes about 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →